HER2, HER3, and TROP2: An Update on Novel Treatments for Key Targets

Review the latest evidence on the optimal use of HER2 HER3 and TROP2 antibody&ndash drug conjugates in breast gastrointestinal and lung cancers with an expert commentary plus a webcast with downloadable slides.

Share

Program Content

Activities

HER2, HER3, TROP2 in Breast Cancer
Targeting HER2, TROP2 and HER3: Spotlight on Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

HER2 and TROP2 in GI Cancer
Focus on HER2 and TROP2 in Gastrointestinal Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

ADCs in Lung Cancer
Antibody–Drug Conjugates in Lung Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2022

Expires: April 07, 2023

No activities added yet

Activities

ADCs and Biomarkers
Update on ADCs and Biomarkers in Breast, Gastrointestinal, and Lung Cancers
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

Faculty

cover img faculity

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine, Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research), Division of Medical Oncology
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

cover img faculity

Yelena Y. Janjigian, MD

Associate Attending Physician
Chief, 
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

cover img faculity

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.